Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0LYQEA
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
ILB-3101
|
|||||
| Synonyms |
ILB-3101; EP0028
Click to Show/Hide
|
|||||
| Organization |
Innolake Biopharma (Originator);Ellipses
|
|||||
| Drug Status |
Phase 1/2
|
|||||
| Drug-to-Antibody Ratio |
3.5
|
|||||
| Antibody Name |
Anti-B7H3 antibody
|
Antibody Info | ||||
| Antigen Name |
CD276 antigen (CD276); Hepatocyte growth factor receptor (MET)
|
Antigen Info | ||||
| Payload Name |
Eribulin
|
Payload Info | ||||
| Therapeutic Target |
Microtubule (MT)
|
Target Info | ||||
| Linker Name |
A cleavable linker
|
Linker Info | ||||
| Conjugate Type |
Undisclosed
|
|||||
The indication landscape of This ADC(2027 Update)
The clinical trial pipeline of This ADC(2027 Update)
| Indication | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | New Drug Application | Approved | ||
|---|---|---|---|---|---|---|---|---|---|
| Breast cancer |
1 Trials
|
||||||||
| Head and neck cancer |
1 Trials
|
||||||||
| Lung cancer |
1 Trials
|
||||||||
| Oesophageal cancer |
1 Trials
|
||||||||
| Ovarian cancer |
1 Trials
|
||||||||
| Prostate cancer |
1 Trials
|
||||||||
| Sarcomas |
1 Trials
|
||||||||
| Unspecific solid tumor |
1 Trials
|
General Information of The Activity Data Related to This ADC
Full List of Activity Data of This Antibody-drug Conjugate
Identified from the Human Clinical Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Patients Enrolled |
Key inclusion: aged 18-80; ECOG 0-1; life expectancy >12 weeks; histologically confirmed advanced/metastatic solid tumors refractory to standard therapy; measurable lesion (s); adequate organ function; negative pregnancy test; effective contraception.
|
||||
| Administration Dosage |
There are eight escalating dose cohorts. Intravenous (IV) administration of ILB-3101 Q3W; Participants will continue treatment until the end of the study in the absence of unacceptable toxicities and confirmed disease progression.
|
||||
| Related Clinical Trial | |||||
| NCT Number | NCT06426680 | Clinical Status | PHASE1 | ||
| Clinical Description | Phase I/II Study of the ILB-3101 in Patients with Advanced Solid Tumors | ||||
| Primary Endpoint |
Primary endpoints include DLT assessment (Day 21), MTD determination (Day 21) for ILB-3101 in advanced solid tumors.
|
||||
| Other Endpoint |
Secondary endpoints comprise ORR (RECIST 1.1, 24 months), AE incidence (CTCAE v5.0, 90 days post-treatment), ADA development (90 days post-treatment), PK parameters (Cmax/Tmax/T1/2/AUC0-t, Cycle 1), and efficacy measures (DOR/DCR/PFS per RECIST 1.1, 24 months).
|
||||